Graphite Bio doses first patient with nula-cel for sickle cell disease; proof-of-concept data mid-2023

LENZ Therapeutics, Inc.

First patient dosed with nula-cel (formerly GPH101) in Phase 1/2 CEDAR trial for sickle cell disease.
Nula-cel is a gene editing therapy designed to directly correct the SCD mutation and restore healthy hemoglobin.
Initial proof-of-concept data from the CEDAR trial expected in mid-2023.
FDA granted Fast Track and Orphan Drug designations for nula-cel.
Phase 1/2 trial to enroll ~15 patients with severe SCD at multiple U.S. sites.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.